ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas

Clin Lung Cancer. 2018 Jan;19(1):e73-e74. doi: 10.1016/j.cllc.2017.08.005. Epub 2017 Sep 1.

Authors

Laetitia Lambros¹, Briac Guibourg¹, Arnaud Uguen²

Affiliations

¹ Department of Pathology, Centre Hospitalier Régional et Universitaire de Brest, Brest, France.
² Department of Pathology, Centre Hospitalier Régional et Universitaire de Brest, Brest, France; Inserm, U1078, Brest, France. Electronic address: arnaud.uguen@chu-brest.fr.

PMID: 28919190
DOI: 10.1016/j.cllc.2017.08.005

No abstract available

Publication types

Letter

MeSH terms

Anaplastic Lymphoma Kinase / genetics*
Antineoplastic Agents / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / genetics*
Crizotinib / therapeutic use
ErbB Receptors / genetics
Gene Rearrangement
Humans
Lung Neoplasms / diagnosis
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics*
Pathology, Molecular
Prognosis
Protein-Tyrosine Kinases / genetics*
Proto-Oncogene Proteins / genetics*
Proto-Oncogene Proteins c-met / genetics*
Proto-Oncogene Proteins p21(ras) / genetics*
Sequence Deletion / genetics*
Treatment Outcome

Substances

Antineoplastic Agents
KRAS protein, human
Proto-Oncogene Proteins
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
EGFR protein, human
ErbB Receptors
MET protein, human
Protein-Tyrosine Kinases
Proto-Oncogene Proteins c-met
ROS1 protein, human
Proto-Oncogene Proteins p21(ras)